Hormonal
Discontinuation of GLP-1 RA therapy is associated with significant weight regain, suggesting that these medications may need to be used as long-term maintenance treatments rather than short-term interventions.
Stopping GLP-1 RAs often leads to significant weight regain. If you are considering stopping, discuss a long-term maintenance plan with your doctor, which may include tapering the dose gradually or continuing a lower dose. This is especially important if you have limited access to the medication.
The concerns surrounding weight regain following treatment discontinuation remain paramount... Emerging data suggests that withdrawal of treatment utilising a gradual dose-reduction approach prior to full discontinuation may have better weight-maintenance outcomes compared to simply stopping from the full dose
Why this rating
Based on cited studies (Wilding et al., 2022; Seier et al., 2024) showing weight regain post-discontinuation.
Source
“From evidence to practice” – Insights from the multidisciplinary team on the optimal integration of <scp>GLP</scp>‐1 receptor agonists in obesity management services
Adrian Brown et al. · Nutrition Bulletin · 2024
DOI 10.1111/nbu.12700
More from this paper
- GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide produce clinically significant weight loss (15-22.5%) and cardiovascular risk reduction, serving as a scalable pharmacological adjunct to lifestyle interventions.Strong
- GLP-1 RA treatment is associated with significant lean tissue (muscle) loss, with studies showing 14-40% of total weight loss being lean mass, necessitating interventions to preserve muscle.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →